Comparison of the effects of intravenous papaverine hydrochloride and oral pavabid HP capsulets on regional cerebral blood flow in normal individuals.
A single-blind study was conducted in 13 right-handed normal male subjects to compare the effects of oral and i.v. papaverine on regional cerebral blood flow (rCBF). Six xenon-133 inhalation rCBF measurements were performed on each subject; three tests--baseline, placebo, and drug evaluations--were carried out on each of two separate days. The oral and i.v. drugs were randomized for first-day administration. rCBF, measured as flow gray (FG), increased significantly (p less than or equal to 0.001) from baseline with both drug forms. Increases of 10.53% and 13.94% (left and right hemispheres, respectively) were demonstrated 90 min after a single 600-mg dose of oral papaverine. Increases of 5.09% and 8.69%, respectively, were recorded immediately after a single 100-mg dose of i.v. papaverine. FG also increased significantly (p less than or equal to 0.001) for both drug forms when compared to that of placebo. Placebo produced only a slight increase (not significant) with both the oral and i.v. groups. The data show increasing rCBF in normal subjects.
D000284:Administration, Oral; D000328:Adult; D002214:Capsules; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage* / Q000097:blood
D002214:Capsules; D010208:Papaverine